Search By:
Products
Injury
Topic
Company
Industry
Abbott may have manipulated the price of Kaletra and Norvir to monopolize the market for anti-AIDS therapies.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topics
- Over Charge
- Price Fixing
- Overcharging for Drug
Products or Services
- Doctors
- Hospitals
- Healthcare Organizations
- Pharmacists
- Norvir
- Kaletra
Injury Type
- Monetary Loss
Investigation Details
Investigation and a pending class action lawsuit on behalf of direct purchasers of the anti-AIDS medicines Norvir and Kaletra.
Norvir serves as a "booster" to prolong the efficacy of other anti-AIDS drugs. Kaletra is a combination of the active ingredient in Norvir and another AIDS drug. The class action lawsuit alleges that Abbott Laboratories quadrupled the price for Norvir, while selling Kaletra below Abbott's cost. These actions were taken in order to simultaneously increase sales of Kaletra and to suppress sales of competitors' AIDS treatments which depend on Norvir as a stand-alone product.
Do not change medications without first consulting your doctor.
Norvir serves as a "booster" to prolong the efficacy of other anti-AIDS drugs. Kaletra is a combination of the active ingredient in Norvir and another AIDS drug. The class action lawsuit alleges that Abbott Laboratories quadrupled the price for Norvir, while selling Kaletra below Abbott's cost. These actions were taken in order to simultaneously increase sales of Kaletra and to suppress sales of competitors' AIDS treatments which depend on Norvir as a stand-alone product.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Abbott (ABT) | Abbott is a medical devices and pharmaceutical company with almost $30 billion in sales for 2008. Abbott employees 72,000 people worldwide at over 100 locations |